| ADHD | Attention-deficit/hyperactivity Disorder |
| ASD | Autism Spectrum Disorder |
| MPH | Methylphenidate |
| ATX | Atomoxetine |
| GFC | Guanfacina |
| DSM | Diagnostic and Statistical Manual of Mental Disorders |
| RCTs | Randomized Controlled Studies |
| ICD | International Classification of Diseases |
| IQ | Intellectual Quotient |
| PRISMA | Preferred Reporting Items for Systematic reviews and Meta-Analyses |
| NOS | Newcastle-Ottawa Scale |
| AHRQ | Agency for Healthcare Research and Quality |
| ABC | Aberrant Behavior Checklist |
| CPRS | Conners Parent Rating Scales–Revised |
| SNAPIV | Swanson, Noland, and Pelham Scale IV |
| CGI | Clinical Global Improvement |
| AE | Adverse Events |
| VR-CBT | Virtual reality-based cognitive-behavioral therapy |
| LSP | Therapist-led program |
| PT | Parent Training |
| RIS | Risperidone |
| ARI | Aripiprazole |
| CONSORT | Consolidated Standards of Reporting Trials |
| ED | Emotion Dysregulation |